Suzette M Evans1, Adam Bisaga. 1. New York State Psychiatric Institute, New York, New York 10032, USA. se18@columbia.edu
Abstract
BACKGROUND: There is growing evidence that gamma-amino butyric acid-B receptor agonists may be effective in the treatment of alcohol abuse or dependence. The primary goal of this study was to determine the safety of baclofen in combination with alcohol consumption in heavy drinkers. In addition, the effects of baclofen alone, and in combination with alcohol, on subjective effects, cognitive performance effects, as well as alcohol craving, were assessed. METHODS:Eighteen non-treatment-seeking heavy social drinkers (mean of 28 drinks per week), who did not meet the criteria for alcohol dependence participated. All individuals were tested using a double-blind double-dummy design with six 2-day inpatient phases. Baclofen (0, 40, and 80 mg) was administered 2.5 hours before alcohol (1.5 g/l body water or approximately 0.75 g/kg) or placebo beverages, given in 4 divided doses every 20 minutes. RESULTS:Baclofen, either alone or in combination with alcohol, produced only modest increases in heart rate and blood pressure and no adverse effects were reported. Baclofen did not increase positive subjective effects (e.g., Stimulant effects, Drug Liking) but did increase sedation and impair performance. Even though both baclofen and alcohol impaired performance, for the most part performance was not impaired to a greater extent when baclofen was combined with alcohol. Among this population of nondependent drinkers, baclofen did not alter alcohol craving or alcohol-induced positive subjective effects. CONCLUSIONS:Baclofen alone has minimal abuse liability in heavy social drinkers, and baclofen is relatively well tolerated and safe when given in combination with intoxicating doses of alcohol.
RCT Entities:
BACKGROUND: There is growing evidence that gamma-amino butyric acid-B receptor agonists may be effective in the treatment of alcohol abuse or dependence. The primary goal of this study was to determine the safety of baclofen in combination with alcohol consumption in heavy drinkers. In addition, the effects of baclofen alone, and in combination with alcohol, on subjective effects, cognitive performance effects, as well asalcohol craving, were assessed. METHODS: Eighteen non-treatment-seeking heavy social drinkers (mean of 28 drinks per week), who did not meet the criteria for alcohol dependence participated. All individuals were tested using a double-blind double-dummy design with six 2-day inpatient phases. Baclofen (0, 40, and 80 mg) was administered 2.5 hours before alcohol (1.5 g/l body water or approximately 0.75 g/kg) or placebo beverages, given in 4 divided doses every 20 minutes. RESULTS:Baclofen, either alone or in combination with alcohol, produced only modest increases in heart rate and blood pressure and no adverse effects were reported. Baclofen did not increase positive subjective effects (e.g., Stimulant effects, Drug Liking) but did increase sedation and impair performance. Even though both baclofen and alcohol impaired performance, for the most part performance was not impaired to a greater extent when baclofen was combined with alcohol. Among this population of nondependent drinkers, baclofen did not alter alcohol craving or alcohol-induced positive subjective effects. CONCLUSIONS:Baclofen alone has minimal abuse liability in heavy social drinkers, and baclofen is relatively well tolerated and safe when given in combination with intoxicating doses of alcohol.
Authors: Giancarlo Colombo; Salvatore Serra; Giovanni Vacca; Mauro A M Carai; Gian Luigi Gessa Journal: Eur J Pharmacol Date: 2006-09-08 Impact factor: 4.432
Authors: Giancarlo Colombo; Salvatore Serra; Giuliana Brunetti; Giuliana Atzori; Marialaura Pani; Giovanni Vacca; Giovanni Addolorato; Wolfgang Froestl; Mauro A M Carai; Gian Luigi Gessa Journal: Alcohol Alcohol Date: 2002 Sep-Oct Impact factor: 2.826
Authors: Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci Journal: Neuropsychopharmacology Date: 2011-10-26 Impact factor: 7.853
Authors: Meghan E Morean; Harriet de Wit; Andrea C King; Mehmet Sofuoglu; Sandra Y Rueger; Stephanie S O'Malley Journal: Psychopharmacology (Berl) Date: 2012-12-28 Impact factor: 4.530
Authors: Lorenzo Leggio; William H Zywiak; John E McGeary; Steven Edwards; Samuel R Fricchione; Jessica R Shoaff; Giovanni Addolorato; Robert M Swift; George A Kenna Journal: Pharmacol Biochem Behav Date: 2012-12-19 Impact factor: 3.533